Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 3
2019 3
2020 7
2021 15
2022 13
2023 15
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis.
Zundell MP, Gottlieb AB, Stanger R. Zundell MP, et al. J Drugs Dermatol. 2024 Feb 1;23(2):97-99. doi: 10.36849/JDD.7639. J Drugs Dermatol. 2024. PMID: 38306127
Secukinumab, an IL-17A inhibitor, is an effective treatment for moderate-to-severe plaque psoriasis but has been implicated in the development or exacerbation of eczematous-like reactions in rare cases. We present a patient with a history of plaque psoriasis who developed …
Secukinumab, an IL-17A inhibitor, is an effective treatment for moderate-to-severe plaque psoriasis but has been implicated in the developme …
Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar.
Steinhoff M, Adeli M, Riad H, Allam M, Hazem A, Alsmadi R, Kamal AM, Ibrahim W, Al-Nesf MA. Steinhoff M, et al. J Dermatolog Treat. 2023 Dec;34(1):2251622. doi: 10.1080/09546634.2023.2251622. J Dermatolog Treat. 2023. PMID: 37700510 Free article. Review.
Atopic dermatitis (AD), a chronic-relapsing inflammatory skin disorder, manifests with intense itching and eczematous lesions impairing quality of life. A heterogeneous population, and regional clinical practices for treating AD warrant the development of guidelines in Qat …
Atopic dermatitis (AD), a chronic-relapsing inflammatory skin disorder, manifests with intense itching and eczematous lesions impairi …
Dupilumab-associated mycosis fungoides: a cross-sectional study.
Hamp A, Hanson J, Schwartz RA, Lambert WC, Alhatem A. Hamp A, et al. Arch Dermatol Res. 2023 Nov;315(9):2561-2569. doi: 10.1007/s00403-023-02652-z. Epub 2023 Jun 4. Arch Dermatol Res. 2023. PMID: 37270763
Only patients with a diagnosis of MF on dupilumab for the treatment of AD and eczematous dermatitis were included.The primary outcome was the length of dupilumab exposure, age, sex, and the onset of MF. ...The results raise the question as to whether the pati …
Only patients with a diagnosis of MF on dupilumab for the treatment of AD and eczematous dermatitis were included.The primary …
Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: Opportunities and challenges.
Zhao A, Pan C, Li M. Zhao A, et al. Pediatr Investig. 2023 Sep 14;7(3):177-190. doi: 10.1002/ped4.12400. eCollection 2023 Sep. Pediatr Investig. 2023. PMID: 37736359 Free PMC article. Review.
Atopic dermatitis (AD) is a complex disease characterized by recurrent eczematous lesions and refractory pruritus that drastically impairs quality of life. ...
Atopic dermatitis (AD) is a complex disease characterized by recurrent eczematous lesions and refractory pruritus that drastically im …
Hyper IgE syndrome-related disease treated with dupilumab: A case report.
Kao AS, Deirawan H, Poowuttikul P, Daveluy S. Kao AS, et al. Clin Case Rep. 2023 Sep 13;11(9):e7614. doi: 10.1002/ccr3.7614. eCollection 2023 Sep. Clin Case Rep. 2023. PMID: 37720709 Free PMC article.
We present a case of a 2-month-old female patient with recurrent infections and diffuse eczematous dermatitis recalcitrant to corticosteroids. A next-generation sequencing NGS gene panel for inherited immune dysfunction syndromes revealed multiple variants of unknown signi …
We present a case of a 2-month-old female patient with recurrent infections and diffuse eczematous dermatitis recalcitrant to cortico …
Stratum Corneum Hydration As a Potential Marker of Response to Dupilumab in Atopic Dermatitis: A Prospective Observational Study.
Montero-Vilchez T, Rodriguez-Pozo JA, Cuenca-Barrales C, Sanabria-de-la-Torre R, Torres-de-Pinedo JM, Arias-Santiago S. Montero-Vilchez T, et al. Dermatitis. 2023 Sep 11. doi: 10.1089/derm.2023.0176. Online ahead of print. Dermatitis. 2023. PMID: 37695812
SCH after 16 weeks treatment on noninvolved skin (odds ratio [OR] = 0.83, P = 0.018) and SCH after 16 weeks treatment on eczematous lesions (OR = 0.86, P = 0.028) were related to dupilumab failure. Conclusion: SCH could be used as a predictive biomarker of dupilu …
SCH after 16 weeks treatment on noninvolved skin (odds ratio [OR] = 0.83, P = 0.018) and SCH after 16 weeks treatment on eczematous l …
Ultra-High Frequency UltraSound (UHFUS) Assessment of Barrier Function in Moderate-to-Severe Atopic Dermatitis during Dupilumab Treatment.
Dini V, Iannone M, Michelucci A, Manzo Margiotta F, Granieri G, Salvia G, Oranges T, Janowska A, Morganti R, Romanelli M. Dini V, et al. Diagnostics (Basel). 2023 Aug 22;13(17):2721. doi: 10.3390/diagnostics13172721. Diagnostics (Basel). 2023. PMID: 37685259 Free PMC article.
Atopic dermatitis (AD) is a chronic multifactorial inflammatory disease characterized by intense itching and inflammatory eczematous lesions. Biological disease-modifying drugs, such as dupilumab are recommended for patients with moderate-to-severe AD, refractory to …
Atopic dermatitis (AD) is a chronic multifactorial inflammatory disease characterized by intense itching and inflammatory eczematous …
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, Caro G, Freites-Martinez A, Hirner JP, Markova A, McLellan BN, Rossi A, Sauder MB, Seminario-Vidal L, Sibaud V, Owen DH, Dulmage BO, Chen ST, Kaffenberger BH. Mital R, et al. Int J Dermatol. 2023 Aug;62(8):1020-1025. doi: 10.1111/ijd.16714. Epub 2023 May 19. Int J Dermatol. 2023. PMID: 37203799
Novel cirAE therapy uses that to our knowledge have not been previously described were captured including tacrolimus for the treatment of follicular, bullous, and eczematous eruptions and phototherapy for eczematous eruptions. Moreover, further evidence of cirAE tre …
Novel cirAE therapy uses that to our knowledge have not been previously described were captured including tacrolimus for the treatment of fo …
Development of Cafe-Au-Lait-Macule Lesions in a Patient After Dupilumab Therapy for Atopic Dermatitis.
Hasanain A, Aleissa AI, AlQurashi W. Hasanain A, et al. Cureus. 2023 Jul 27;15(7):e42581. doi: 10.7759/cureus.42581. eCollection 2023 Jul. Cureus. 2023. PMID: 37641759 Free PMC article.
We present a case of cafe-au-lait macules as an adverse effect of dupilumab therapy in a patient with atopic dermatitis. The patient in this case had been receiving dupilumab therapy for atopic dermatitis. The eczematous lesions had seen improvement; however, …
We present a case of cafe-au-lait macules as an adverse effect of dupilumab therapy in a patient with atopic dermatitis. The patient …
54 results